Utility of uroplakin II expression as a marker of urothelial carcinoma

Wei Tian, Gunes Guner, Hiroshi Miyamoto, Ashley Cimino-Mathews, Nilda Gonzalez-Roibon, Pedram Argani, Xuan Li, Rajni Sharma, Andrea P. Subhawong, Katayoon Rezaei, Trinity J. Bivalacqua, Jonathan I. Epstein, Justin A. Bishop, George J. Netto

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Uroplakins are markers of terminally differentiated urothelium. Uroplakin II (UPII) is a newly described sensitive marker for urothelial carcinoma (UC). The expression profile of UPII in different types of UC and its utility in the diagnostic setting are needed. We evaluated UPII expression in bladder tissue microarrays, including urothelial neoplasm of low malignant potential (n = 8), low-grade papillary UC (n = 72), noninvasive high-grade papillary UC (n = 77), UC in situ (n = 27), and invasive high-grade UC (INVUC) (n = 122). UPII expression in 52 breast carcinomas and 38 high-grade prostate adenocarcinomas was also assessed. UPII expression was compared with GATA binding protein 3 (GATA3) and estrogen receptor for its role in facilitating the differential diagnosis of the above 3 types of malignancy. UPII labeling was seen in 83.0% of UC overall, including 95.7% of noninvasive UC and 65.6% of INVUC. UPII labeling was not found in any breast and prostate carcinomas. In comparison, GATA3 labeling was seen in 91.6% of all UCs, including 96.4% of noninvasive UCs and 85.1% of INVUC, with stronger intensity and extent compared with UPII (P <.005). GATA3 labeled 2 (5%) of 38 high-grade prostate adenocarcinoma. Estrogen receptor nuclear labeling was seen in 13.0% of UCs and 12.5% of prostate carcinomas. UPII was highly specific (100%) but only moderately sensitive for UC and can therefore be a potentially useful marker to identify urothelial lineage and help distinguish UC from prostate cancer or, in conjunction with GATA3, from metastatic breast cancer.

Original languageEnglish (US)
Pages (from-to)58-64
Number of pages7
JournalHuman Pathology
Volume46
Issue number1
DOIs
StatePublished - Jan 1 2015

Fingerprint

Uroplakin II
Carcinoma
Prostate
Carrier Proteins
Papillary Carcinoma
Estrogen Receptors
Uroplakins
Adenocarcinoma
Breast Neoplasms
Urothelium
Carcinoma in Situ
Neoplasms
Prostatic Neoplasms

Keywords

  • Bladder cancer
  • Breast carcinoma
  • GATA3
  • Immunohistochemistry
  • Uroplakin II

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Medicine(all)

Cite this

Tian, W., Guner, G., Miyamoto, H., Cimino-Mathews, A., Gonzalez-Roibon, N., Argani, P., ... Netto, G. J. (2015). Utility of uroplakin II expression as a marker of urothelial carcinoma. Human Pathology, 46(1), 58-64. https://doi.org/10.1016/j.humpath.2014.09.007

Utility of uroplakin II expression as a marker of urothelial carcinoma. / Tian, Wei; Guner, Gunes; Miyamoto, Hiroshi; Cimino-Mathews, Ashley; Gonzalez-Roibon, Nilda; Argani, Pedram; Li, Xuan; Sharma, Rajni; Subhawong, Andrea P.; Rezaei, Katayoon; Bivalacqua, Trinity J.; Epstein, Jonathan I.; Bishop, Justin A.; Netto, George J.

In: Human Pathology, Vol. 46, No. 1, 01.01.2015, p. 58-64.

Research output: Contribution to journalArticle

Tian, W, Guner, G, Miyamoto, H, Cimino-Mathews, A, Gonzalez-Roibon, N, Argani, P, Li, X, Sharma, R, Subhawong, AP, Rezaei, K, Bivalacqua, TJ, Epstein, JI, Bishop, JA & Netto, GJ 2015, 'Utility of uroplakin II expression as a marker of urothelial carcinoma', Human Pathology, vol. 46, no. 1, pp. 58-64. https://doi.org/10.1016/j.humpath.2014.09.007
Tian W, Guner G, Miyamoto H, Cimino-Mathews A, Gonzalez-Roibon N, Argani P et al. Utility of uroplakin II expression as a marker of urothelial carcinoma. Human Pathology. 2015 Jan 1;46(1):58-64. https://doi.org/10.1016/j.humpath.2014.09.007
Tian, Wei ; Guner, Gunes ; Miyamoto, Hiroshi ; Cimino-Mathews, Ashley ; Gonzalez-Roibon, Nilda ; Argani, Pedram ; Li, Xuan ; Sharma, Rajni ; Subhawong, Andrea P. ; Rezaei, Katayoon ; Bivalacqua, Trinity J. ; Epstein, Jonathan I. ; Bishop, Justin A. ; Netto, George J. / Utility of uroplakin II expression as a marker of urothelial carcinoma. In: Human Pathology. 2015 ; Vol. 46, No. 1. pp. 58-64.
@article{859caa2d224743b08f10fbfb3448b2c7,
title = "Utility of uroplakin II expression as a marker of urothelial carcinoma",
abstract = "Uroplakins are markers of terminally differentiated urothelium. Uroplakin II (UPII) is a newly described sensitive marker for urothelial carcinoma (UC). The expression profile of UPII in different types of UC and its utility in the diagnostic setting are needed. We evaluated UPII expression in bladder tissue microarrays, including urothelial neoplasm of low malignant potential (n = 8), low-grade papillary UC (n = 72), noninvasive high-grade papillary UC (n = 77), UC in situ (n = 27), and invasive high-grade UC (INVUC) (n = 122). UPII expression in 52 breast carcinomas and 38 high-grade prostate adenocarcinomas was also assessed. UPII expression was compared with GATA binding protein 3 (GATA3) and estrogen receptor for its role in facilitating the differential diagnosis of the above 3 types of malignancy. UPII labeling was seen in 83.0{\%} of UC overall, including 95.7{\%} of noninvasive UC and 65.6{\%} of INVUC. UPII labeling was not found in any breast and prostate carcinomas. In comparison, GATA3 labeling was seen in 91.6{\%} of all UCs, including 96.4{\%} of noninvasive UCs and 85.1{\%} of INVUC, with stronger intensity and extent compared with UPII (P <.005). GATA3 labeled 2 (5{\%}) of 38 high-grade prostate adenocarcinoma. Estrogen receptor nuclear labeling was seen in 13.0{\%} of UCs and 12.5{\%} of prostate carcinomas. UPII was highly specific (100{\%}) but only moderately sensitive for UC and can therefore be a potentially useful marker to identify urothelial lineage and help distinguish UC from prostate cancer or, in conjunction with GATA3, from metastatic breast cancer.",
keywords = "Bladder cancer, Breast carcinoma, GATA3, Immunohistochemistry, Uroplakin II",
author = "Wei Tian and Gunes Guner and Hiroshi Miyamoto and Ashley Cimino-Mathews and Nilda Gonzalez-Roibon and Pedram Argani and Xuan Li and Rajni Sharma and Subhawong, {Andrea P.} and Katayoon Rezaei and Bivalacqua, {Trinity J.} and Epstein, {Jonathan I.} and Bishop, {Justin A.} and Netto, {George J.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1016/j.humpath.2014.09.007",
language = "English (US)",
volume = "46",
pages = "58--64",
journal = "Human Pathology",
issn = "0046-8177",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Utility of uroplakin II expression as a marker of urothelial carcinoma

AU - Tian, Wei

AU - Guner, Gunes

AU - Miyamoto, Hiroshi

AU - Cimino-Mathews, Ashley

AU - Gonzalez-Roibon, Nilda

AU - Argani, Pedram

AU - Li, Xuan

AU - Sharma, Rajni

AU - Subhawong, Andrea P.

AU - Rezaei, Katayoon

AU - Bivalacqua, Trinity J.

AU - Epstein, Jonathan I.

AU - Bishop, Justin A.

AU - Netto, George J.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Uroplakins are markers of terminally differentiated urothelium. Uroplakin II (UPII) is a newly described sensitive marker for urothelial carcinoma (UC). The expression profile of UPII in different types of UC and its utility in the diagnostic setting are needed. We evaluated UPII expression in bladder tissue microarrays, including urothelial neoplasm of low malignant potential (n = 8), low-grade papillary UC (n = 72), noninvasive high-grade papillary UC (n = 77), UC in situ (n = 27), and invasive high-grade UC (INVUC) (n = 122). UPII expression in 52 breast carcinomas and 38 high-grade prostate adenocarcinomas was also assessed. UPII expression was compared with GATA binding protein 3 (GATA3) and estrogen receptor for its role in facilitating the differential diagnosis of the above 3 types of malignancy. UPII labeling was seen in 83.0% of UC overall, including 95.7% of noninvasive UC and 65.6% of INVUC. UPII labeling was not found in any breast and prostate carcinomas. In comparison, GATA3 labeling was seen in 91.6% of all UCs, including 96.4% of noninvasive UCs and 85.1% of INVUC, with stronger intensity and extent compared with UPII (P <.005). GATA3 labeled 2 (5%) of 38 high-grade prostate adenocarcinoma. Estrogen receptor nuclear labeling was seen in 13.0% of UCs and 12.5% of prostate carcinomas. UPII was highly specific (100%) but only moderately sensitive for UC and can therefore be a potentially useful marker to identify urothelial lineage and help distinguish UC from prostate cancer or, in conjunction with GATA3, from metastatic breast cancer.

AB - Uroplakins are markers of terminally differentiated urothelium. Uroplakin II (UPII) is a newly described sensitive marker for urothelial carcinoma (UC). The expression profile of UPII in different types of UC and its utility in the diagnostic setting are needed. We evaluated UPII expression in bladder tissue microarrays, including urothelial neoplasm of low malignant potential (n = 8), low-grade papillary UC (n = 72), noninvasive high-grade papillary UC (n = 77), UC in situ (n = 27), and invasive high-grade UC (INVUC) (n = 122). UPII expression in 52 breast carcinomas and 38 high-grade prostate adenocarcinomas was also assessed. UPII expression was compared with GATA binding protein 3 (GATA3) and estrogen receptor for its role in facilitating the differential diagnosis of the above 3 types of malignancy. UPII labeling was seen in 83.0% of UC overall, including 95.7% of noninvasive UC and 65.6% of INVUC. UPII labeling was not found in any breast and prostate carcinomas. In comparison, GATA3 labeling was seen in 91.6% of all UCs, including 96.4% of noninvasive UCs and 85.1% of INVUC, with stronger intensity and extent compared with UPII (P <.005). GATA3 labeled 2 (5%) of 38 high-grade prostate adenocarcinoma. Estrogen receptor nuclear labeling was seen in 13.0% of UCs and 12.5% of prostate carcinomas. UPII was highly specific (100%) but only moderately sensitive for UC and can therefore be a potentially useful marker to identify urothelial lineage and help distinguish UC from prostate cancer or, in conjunction with GATA3, from metastatic breast cancer.

KW - Bladder cancer

KW - Breast carcinoma

KW - GATA3

KW - Immunohistochemistry

KW - Uroplakin II

UR - http://www.scopus.com/inward/record.url?scp=84915749708&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84915749708&partnerID=8YFLogxK

U2 - 10.1016/j.humpath.2014.09.007

DO - 10.1016/j.humpath.2014.09.007

M3 - Article

C2 - 25449628

AN - SCOPUS:84915749708

VL - 46

SP - 58

EP - 64

JO - Human Pathology

JF - Human Pathology

SN - 0046-8177

IS - 1

ER -